Evidence map›Paper›PMID 38778403›Full record

ArticleBMC medical genomics2024

Identification and validation of a novel risk model based on cuproptosis‑associated m6A for head and neck squamous cell carcinoma.

Zhongxu Xing, Yijun Xu, Xiaoyan Xu, Kaiwen Yang, Songbing Qin, Yang Jiao, Lili Wang

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhongxu XingDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 21500, China.
Yijun XuDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 21500, China.
Xiaoyan XuDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 21500, China.
Kaiwen YangDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 21500, China.
Songbing QinDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 21500, China.
Yang JiaoState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China. jiaoyang@suda.edu.cn.
Lili WangDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 21500, China. wanglili@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) is a prevalent cancer with a poor survival rate due to anatomical limitations of the head and a lack of reliable biomarkers. Cuproptosis represents a novel cellular regulated death pathway, and N6-methyladenosine (m6A) is the most common internal RNA modification in mRNA. They are intricately connected to tumor formation, progression, and prognosis. This study aimed to construct a risk model for HNSCC using a set of mRNAs associated with m6A regulators and cuproptosis genes (mcrmRNA).

methodsRNA-seq and clinical data of HNSCC patients from The Cancer Genome Atlas (TCGA) database were analyzed to develop a risk model through the least absolute shrinkage and selection operator (LASSO) analysis. Survival analysis and receiver operating characteristic (ROC) analysis were performed for the high- and low-risk groups. Additionally, the model was validated using the GSE41613 dataset from the Gene Expression Omnibus (GEO) database. GSEA and CIBERSORT were applied to investigate the immune microenvironment of HNSCC.

resultsA risk model consisting of 32 mcrmRNA was developed using the LASSO analysis. The risk score of patients was confirmed to be an independent prognostic indicator by multivariate Cox analysis. The high-risk group exhibited a higher tumor mutation burden. Additionally, CIBERSORT analysis indicated varying levels of immune cell infiltration between the two groups. Significant disparities in drug sensitivity to common medications were also observed. Enrichment analysis further unveiled significant differences in metabolic pathways and RNA processing between the two groups.

conclusionsOur risk model can predict outcomes for HNSCC patients and offers valuable insights for personalized therapeutic approaches.

Indexed as

AdenosineHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisRisk AssessmentRNA, MessengerTumor MicroenvironmentAdenosineBiomarkers, TumorN-methyladenosineRNA, MessengerCuproptosisHead and neck squamous cell carcinomaPrognosisRisk modelRNA methylation regulation

Identifiers

PMID38778403
PMCPMC11110395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.